



Published in final edited form as:

Cancer Prev Res (Phila). 2010 November ; 3(11): 1503–. doi:10.1158/1940-6207.CAPR-10-0261.

Correction

Correction: Finasteride Modifies the Relation between Serum C–Peptide and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial

In this article (*Cancer Prev Res* 2010 3:279-289), which was published in the March 2010 issue of *Cancer Prevention Research* (1), Table 4 included a mistake in the calculation of some of the odds ratios. The corrected table appears below:

References

1. Neuhouser ML, Till C, Kristal AR, et al. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. *Can Prev Res*. 2010; 3:279–89.

Table 4
Adiposity/C-peptide interactions in relation to high-grade prostate cancer in the PCPT (placebo arm only)

	Total n	C-peptide <3.08 ng/mL		C-peptide ≥3.08 ng/mL	
		Cases (n)	OR (95% CI)	Cases (n)	OR (95% CI)
BMI					
Normal	49	25	1.0 (reference)	24	1.43 (0.77-2.66)
Overweight	106	41	0.80 (0.47-1.36)	65	1.59 (0.96-2.64)
Obese	57	19	1.62 (0.84-3.15)	38	1.67 (0.95-2.91)
Waist Circumference					
Waist <102	92	45	1.0 (reference)	47	1.50 (0.95-2.38)
Waist ≥102	104	34	0.98 (0.58-1.66)	70	1.52 (0.93-2.49)
Waist:Hip Ratio					
Waist:Hip <1.0	160	69	1.0 (reference)	91	1.56 (1.09-2.23)
Waist:Hip ≥1.0	36	10	0.73(0.35-1.49)	26	1.11 (0.65-1.90)
Very High Risk					
Low Risk	145	63	1.0 (reference)	82	1.71 (1.19-2.47)
High Risk	46	15	1.20 (0.57-2.54)	31	1.21 (0.62-2.37)